SCHEMBL6324285

SCHEMBL6324285

Fc1cccc(F)c1-c1cccc2[nH]ccc12

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 3/20 0.51
AHR P35869 1/20 0.47
MAPK14 Q16539 4/20 0.47
TRPA1 O75762 1/20 0.45
CSNK2B P67870 1/20 0.44
CSNK2A1 P68400 1/20 0.44
ASH1L Q9NR48 1/20 0.44
PIK3CB P42338 2/20 0.42
PIK3CG P48736 1/20 0.41
HSD17B1 P14061 1/20 0.40
HSD17B2 P37059 1/20 0.40
RHEB Q15382 3/20 0.40
BRD4 O60885 1/20 0.40
MAPK1 P28482 2/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
DHFR P00374 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6330094 0.85 MAPK14 (0.53) PIK3CDAHRMAPK14TRPA1CSNK2B
SCHEMBL2780172 0.83 PIK3CD (0.50) PIK3CDAHRMAPK14TRPA1CSNK2B
SCHEMBL18805064 0.81 AHR (0.56) PIK3CDAHRMAPK14TRPA1ASH1L
SCHEMBL680718 0.81 AHR (0.56) PIK3CDAHRMAPK14TRPA1ASH1L
SCHEMBL30065220 0.81 AHR (0.56) PIK3CDAHRMAPK14TRPA1ASH1L
SCHEMBL20540332 0.81 PIK3CD (0.64) PIK3CDAHRMAPK14CSNK2BCSNK2A1
SCHEMBL6322152 0.76 PIK3CD (0.64) PIK3CDAHRMAPK14TRPA1CSNK2B
SCHEMBL10945814 0.75 PIK3CD (0.75) PIK3CDAHRMAPK14CSNK2BCSNK2A1
SCHEMBL6322290 0.75 TRPA1 (0.59) PIK3CDAHRMAPK14TRPA1CSNK2B
SCHEMBL6322590 0.74 PIK3CD (0.57) PIK3CDAHRMAPK14TRPA1CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 PIK3CD 365/4885AHR 656/4885MAPK14 535/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 PIK3CD 365/4885AHR 656/4885MAPK14 535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.